



BSI Standards Publication

Cardiovascular implants and extracorporeal systems — Cardiovascular absorbable implants

National foreword

This Published Document is the UK implementation of ISO/TS 17137:2019. It supersedes PD ISO/TS 17137:2014, which is withdrawn.

The UK participation in its preparation was entrusted to Technical Committee CH/150/2, Cardiovascular implants.

A list of organizations represented on this committee can be obtained on request to its secretary.

This publication does not purport to include all the necessary provisions of a contract. Users are responsible for its correct application.

© The British Standards Institution 2019
Published by BSI Standards Limited 2019

ISBN 978 0 539 02806 5

ICS 11.040.40

Compliance with a British Standard cannot confer immunity from legal obligations.

This Published Document was published under the authority of the Standards Policy and Strategy Committee on 30 September 2019.

Amendments/corrigenda issued since publication

| Date | Text affected |
|------|---------------|
|------|---------------|

TECHNICAL SPECIFICATION

**ISO/TS
17137**

Second edition
2019-09-13

Cardiovascular implants and extracorporeal systems — Cardiovascular absorbable implants

*Implants cardiovasculaires et systèmes extracorporels — Implants
cardiovasculaires absorbables*



Reference number
ISO/TS 17137:2019(E)

© ISO 2019



COPYRIGHT PROTECTED DOCUMENT

© ISO 2019, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Ch. de Blandonnet 8 • CP 401
CH-1214 Vernier, Geneva, Switzerland
Tel. +41 22 749 01 11
Fax +41 22 749 09 47
copyright@iso.org
www.iso.org

Contents

| | Page |
|--|----------|
| Foreword | v |
| Introduction | vi |
| 1 Scope | 1 |
| 2 Normative references | 1 |
| 3 Terms and definitions | 2 |
| 4 Device design, fabrication, packaging, and use considerations | 2 |
| 4.1 Classification | 2 |
| 4.2 Intended clinical performance | 3 |
| 4.3 Intended clinical use | 3 |
| 4.4 Materials | 3 |
| 4.5 Packaging, labelling, and sterilization | 4 |
| 4.5.1 Packaging | 4 |
| 4.5.2 Labelling | 4 |
| 4.5.3 Sterilization | 5 |
| 4.6 Product shelf-life considerations | 6 |
| 4.6.1 General information | 6 |
| 4.6.2 Real-time aging | 7 |
| 4.6.3 Accelerated aging | 7 |
| 4.7 Risk management | 7 |
| 4.7.1 General | 7 |
| 4.7.2 Failure modes | 7 |
| 4.7.3 Risk mitigation | 8 |
| 4.7.4 Specific aspects for absorbable implants | 8 |
| 5 Design evaluation | 8 |
| 5.1 Evaluation overview and general considerations | 8 |
| 5.1.1 Overview | 8 |
| 5.1.2 General considerations | 10 |
| 5.1.3 Summary of <i>in vitro</i> evaluation steps | 11 |
| 5.2 <i>in vitro</i> procedural evaluation | 12 |
| 5.2.1 Conditioning of test samples | 12 |
| 5.2.2 Assessment of delivery and placement | 12 |
| 5.2.3 Assessment of initial function post-deployment | 13 |
| 5.3 <i>in vitro</i> degradation evaluation | 13 |
| 5.3.1 General | 13 |
| 5.3.2 Sample conditioning | 14 |
| 5.3.3 Mechanical evaluation | 14 |
| 5.3.4 Cyclic fatigue durability evaluation | 15 |
| 5.3.5 Physical/chemical degradation evaluation | 15 |
| 5.3.6 Imaging compatibility evaluation | 17 |
| 5.4 Biological evaluation | 17 |
| 5.4.1 General considerations | 17 |
| 5.4.2 Sterilization considerations | 18 |
| 5.4.3 Drug-device combination product considerations | 18 |
| 5.5 <i>in vitro-in vivo</i> correlation | 19 |
| 5.6 <i>in vivo</i> pre-clinical evaluation | 19 |
| 5.6.1 Purpose | 19 |
| 5.6.2 Specific objectives | 20 |
| 5.6.3 Protocol | 20 |
| 5.6.4 Data collection | 22 |
| 5.6.5 Test report and additional information | 22 |
| 5.7 Clinical evaluation | 22 |
| 5.7.1 Purpose | 22 |

| | | |
|---|----------------------------------|-----------|
| 5.7.2 | Specific objectives..... | 23 |
| 5.7.3 | Clinical investigation plan..... | 23 |
| 5.7.4 | Data collection | 23 |
| 5.7.5 | Final report..... | 24 |
| 5.7.6 | Post market surveillance..... | 24 |
| Annex A (informative) Explanation on nomenclature of absorb, degrade and related terms | | 25 |
| Bibliography | | 26 |

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 150, *Implants for surgery*, Subcommittee SC 2, *Cardiovascular implants and extracorporeal systems*.

This second edition cancels and replaces the first edition (ISO/TS 17137:2014), which has been technically revised.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

Absorbable cardiovascular implants are medical devices with various clinical indications for use in the human cardiovascular blood system. An absorbable cardiovascular implant, or at least a portion thereof, is designed to intentionally degrade over time into degradation products that are absorbed by the body through metabolism, assimilation, and/or excretion (elimination). Such implants can be either surgically or interventionally introduced to the site of treatment.

This document outlines requirements for intended performance, design attributes, materials, design evaluation, manufacturing, sterilization, packaging, and information supplied by the manufacturer. This document should be considered as a supplement to ISO 14630, which specifies general requirements for the performance of non-active surgical implants. This document should also be considered as a supplement to relevant device-specific standards such as the ISO 25539 series specifying requirements for endovascular devices, which do not address degradation and other time dependent aspects of absorbable implants and coatings. Additionally, this document should be considered in conjunction with ISO 14155, which specifies proper practices in clinical investigations.

This document is not comprehensive with respect to the pharmacological evaluation of cardiovascular absorbable implants. More detailed safety and performance requirements for pharmacological agents included in the absorbable cardiovascular implant are described in ISO 12417-1.

Only issues related to degradation and absorption combined with the cardiovascular implant are covered by this document. Due to the variations in the design of implants covered by this document and in some cases due to the relatively recent development of some of these implants (e.g. absorbable stents), acceptable standardized *in vitro* tests and clinical results are not always available. As further scientific and clinical data become available, appropriate revision of this document will be necessary.

NOTE For issues related to the common mechanical function of the cardiovascular implant, the reader might find it useful to consider a number of other international standards (see Bibliography).

Cardiovascular implants and extracorporeal systems — Cardiovascular absorbable implants

1 Scope

This document outlines design evaluation guidelines for absorbable cardiovascular implants used to treat vessels and/or the vascular space within the circulatory system, including the heart and all vasculature. This document is meant to supplement device-specific standards by providing guidelines specific for absorbable implants and/or components

This document is applicable to implants in direct contact with the cardiovascular system, where the intended action is upon the circulatory system. This document does not address the specific evaluation of issues associated with viable tissues, viable cells, and/or implants with non-viable biological materials and their derivatives. Additionally, procedures and devices used prior to and following the introduction of the absorbable cardiovascular implant (e.g. balloon angioplasty devices) are excluded from the scope of This document if they do not affect the absorption aspects of the implant. A cardiovascular absorbable implant may incorporate substance(s) which, if used separately, can be considered to be a medicinal product (drug product) but the action of the medicinal substance is ancillary to that of the implant and supports the primary mode of action of the implant.

NOTE 1 Some aspects of absorbable components of cardiovascular device-drug combination products (e.g. coatings) in their connection with drug-related aspects of the device are addressed in ISO 12417-1.

NOTE 2 An explanation of the nomenclature of absorb, degrade and related terms can be found in [Annex A](#) of this document.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 5840 (all parts), *Cardiovascular implants — Cardiac valve prostheses*

ISO 10993 (all parts), *Biological evaluation of medical devices*

ISO 11135, *Sterilization of health-care products — Ethylene oxide — Requirements for the development, validation and routine control of a sterilization process for medical devices*

ISO 11137 (all parts), *Sterilization of health care products — Radiation*

ISO 11607-1, *Packaging for terminally sterilized medical devices — Part 1: Requirements for materials, sterile barrier systems and packaging systems*

ISO 12417-1, *Cardiovascular implants and extracorporeal systems — Vascular device-drug combination products — Part 1: General requirements*

ISO 14155, *Clinical investigation of medical devices for human subjects — Good clinical practice*

ISO 14630, *Non-active surgical implants — General requirements*

ISO 14937, *Sterilization of health care products — General requirements for characterization of a sterilizing agent and the development, validation and routine control of a sterilization process for medical devices*

ISO 14971, *Medical devices — Application of risk management to medical devices*